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A large variety of conditions cause chronic liver 
disease (CLD) in children. In infants, biliary atresia 
is the most common cause followed by inherited 
metabolic disease, genetic abnormalities, and other 
biliary abnormalities. Auto-immune hepatitis, non-
alcoholic fatty liver disease, chronic viral hepatitis and inherited 
metabolic disease are leading causes in older children.
The effect that chronic liver disease has on a child’s nutritional 
status and health is determined by the cause and severity of 
the liver disease and the age of onset. There is a bidirectional 
interaction between CLD and malnutrition: CLD often leads to 
malnutrition, and malnutrition adversely affects the course of 
liver disease. 
The progressive loss of liver function and development of 
cirrhosis in children with CLD causes haemodynamic and metabolic 
disturbances and severe complications such as hepatopulmonary 
syndrome and renal failure. Liver transplantation is the only curative 
option for many children. For these children nutritional support 
improves quality of life, improves post-transplant survival, and 
prevents serious complications such as rickets, severe muscle loss, 
and haemorrhagic disease. In some children the liver disease requires 
specific nutritional therapy such as a galactose-free diet. However, 
even children with less severe liver disease require nutritional 
assessment and intervention to prevent osteopenia and the 
complications of micronutrient deficiency. 
Current recommendations are based on our understanding of 
the effect of CLD on nutritional status, digestion and absorption of 
nutrients, metabolism and limited clinical trials.
Prevalence of malnutrition
Approximately 60 - 80% of children with CLD awaiting liver 
transplantation are malnourished;[1] weight, height, head circum-
ference, skinfold thickness and mid-upper-arm circumference are 
reduced.[2,3] These changes are particularly prominent in children 
with severe cholestatic liver disease such as biliary atresia and the 
severe intrahepatic causes of CLD. 
Effect of malnutrition on prognosis
The degree of malnutrition reflects the severity of liver disease 
and is included in the assessment of end-stage liver disease in 
children (paediatric end-stage liver disease (PELD) score).[4] 
Malnourished children have increased post-transplant mortality 
and morbidity.[4] In addition, specific nutrient deficiencies can 
cause serious complications, e.g. vitamin deficiencies (A, E, D, K) 
and essential fatty acid deficiency. 
Nutritional consequences of CLD
CLD significantly alters body composition and metabolism. Fat 
mass is reduced and eventually lean body mass as well. Resting 
energy expenditure and total energy expenditure are increased 
by approximately 30% in young children with CLD.[5,6] Children 
preferentially oxidise fat in the postabsorptive phase.[5,7] Oxidation of 
branched-chain amino acids such as leucine is increased. 
Hormonal changes contribute to poor growth and changes in 
body composition. Growth hormone receptor expression is reduced, 
leading to low insulin-like growth factor 1 (IGF-1). In adolescents, 
puberty is often delayed and hypogonadism is common.[8] 
Considered together, these changes have important implications 
for nutritional support: energy intake should be high, periods of 
fasting avoided, protein intake not restricted, and branched-chain 
amino acids supplemented. Initiation of nutritional support should 
not be delayed as nutritional recovery may be difficult to achieve once 
children have developed severe malnutrition.
Liver-associated metabolic bone disease with pathological 
fractures is a significant complication in children with cirrhotic and 
non-cirrhotic CLD.[9] The term ‘hepatic osteodystrophy’ describes 
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Anorexia, malabsorption and metabolic derangements contribute to the malnutrition that occurs in most children with chronic liver 
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enriched with medium-chain fatty acids because of their better absorption in cholestatic liver disease. High-dose fat-soluble vitamin 
supplements are given while care is taken to avoid toxicity. Initial doses are two to three times the RDI and then adjusted according to serum 
levels or international normalised ratio (INR) in the case of vitamin K.
Children with good appetites are fed orally. Feeds should be more regular than for other children to avoid prolonged periods of fasting 
and improve energy intake. Some children require supplementary nasogastric feeds to increase energy intake and avoid overnight fasting.
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this complex of structural and metabolic bone changes, including 
osteoporosis and osteomalacia or rickets in children.
Osteoporosis, where the bone mineral density (BMD) is decreased, 
is a common cause for fractures (prevalence 10 - 28%),[8] and 
although mostly asymptomatic, has a significant negative impact 
on morbidity and quality of life.[10] In contrast to adults, children 
have a greater potential for spontaneous recovery of BMD after liver 
transplant, usually after 1 year.[8] Immobility and low muscle force in 
this popula tion further contribute to the low bone mass.[8]
In children, not only the existing bone is affected, but also the growth 
plates, adding rickets (the consequence of vitamin D deficiency on 
growing bone), spine abnormalities and growth failure to the equation.[8]
Vitamin D deficiency is thought to be a major causative factor for hepatic 
osteodystrophy. Malabsorption of fat-soluble vitamins due to deficient 
Table 1. Clinical nutritional assessment in paediatric chronic liver disease
Nutritional 
element/factor Assessment tools Deficiency Toxic effects Specific recommendations
Macronutrients
Energy/caloric intake Anthropometric 
measurements
Mid-upper-arm 
circumference
Triceps and subscapular 
skinfold thickness
Serial measurements 
weight/height
Indirect calorimetry
Fat malabsorption
Reduced muscle bulk
Reduced subcutaneous fat
Alopecia, thin sparse hair
Pigmentary changes skin
Parotid enlargement
Steatorrhoea
Financial burden 
Essential fatty acid 
deficiency
Calorie goal of 130 - 180% of RDI 
based on weight or height 50th 
centile
MCT oil 1 - 2 mL/kg/d in 2 - 4 doses
Add glucose polymers (Polycose 
powder or solutions) and supple-
mental night-time nasogastric drip 
feeds
MCT infant formulas (Pregestimil, 
Alimentum, Prenan)
Carbohydrate Serum glucose Monitor for hypoglycaemia during 
fasting, illness or reduced intake
Protein Mid-upper-arm 
circumference
Serum albumin, pre-
albumin, RBP, transferrin
Reduced muscle bulk
Alopecia, thin sparse 
hair
Pigmentary changes skin
Parotid enlargement
Peripheral oedema
Psychomotor changes, 
irritability
Infants: protein intake 3 - 4 g/kg/d
Hepatic encephalopathy: protein 
intake 0.5 - 1.0 g/kg/d
Branched-chain amino acid 
supplements
Fat
Essential fatty acid 
deficiency
Triene:tetraene ratio >0.3
Decreased linoleic acid
Skin dryness, peeling
Alopecia
Oral vegetable/corn oil or intravenous 
lipid emulsions
Micronutrients
Vitamin A Deficiency:
Retinol: RBP molar 
ratio <0.8 or 
serum retinol <20 µg/dL
Xerosis
Bitot spots
Night blindness
Dry skin
Follicular keratosis
Possible immune 
dysfunction
Liver fibrosis
Hypercalcaemia
Pseudotumor 
cerebri
Painful bone lesions
Vitamin A 5 000 - 25 000 U/d po
Vitamin D Deficiency:
25-OH vitamin D level 
<30 ng/mL
Calcium, phosphorus 
levels
Hypocalcaemia
Hypophosphatemia
Muscle hypotonia
Poor dentition
Rickets:
Bowed legs
Epiphyseal enlargement
Rachitic rosary
Craniotabes 
Frontal bossing
Delayed fontanel closure
Hypercalcaemia
Pseudotumor cerebri
Nephrocalcinosis
Ergocalciferol: 3 - 10 times RDI
Cholecalciferol based on weight and 
vitamin D levels
Weight <40 kg Weight >40 kg
<10 ng/mL: 
100 U/kg/d
<10 ng/mL: 
5 000 U/d
11 - 19 ng/mL: 
75 U/kg/d
11 - 19 ng/mL: 
4 000 U/d
20 - 29 ng/mL: 
50 U/kg/d
20 - 29 ng/mL: 
3 000 U/d
Continued ...
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intraluminal bile acids, decreased exposure to direct sunlight and poor 
25-hydroxylation in end-stage liver failure, are all contributing factors. 
Secondary hyperparathyroidism, in response to low serum calcium, 
increases bone resorption and intestinal calcium absorption but also 
increases phosphate loss in the kidney. 
Other contributing factors are suboptimal calcium intake, 
hypogonadism, vitamin K deficiency (important role in osteocalcin 
homeostasis), and corticosteroid treatment.[11] 
Causes of malnutrition
The cause of malnutrition in CLD is multifactorial. Intake in children 
is poor, with as many as 70% of children consuming less than 
recommended.[2] Nausea, anorexia, mucosal congestion, decreased 
intestinal motility, early satiety due to organomegaly and ascites, and 
dietary modifications that require unpalatable diets all contribute to 
reduced intake.
Infants and young children derive approximately 50% of their energy 
from dietary fat. Absorption of long-chain fatty acids is reduced as a result of 
reduced luminal bile acid concentration depriving children of this important 
source of energy and often leading to essential fatty acid deficiency.[12] 
Assessment of nutritional status
The nutritional status of children is assessed to identify those 
who require additional nutrition support and monitor response to 
Table 1. (continued) Clinical nutritional assessment in paediatric chronic liver disease 
Nutritional element/
factor Assessment tools Deficiency Toxic effects Specific recommendations
Micronutrients
Vitamin E Deficiency:
Vitamin E:total lipid ratio
<0.6 mg/g (<1 y)
<0.8 mg/g (>1 y)
Poor nerve conduction
Hypo/areflexia
Ataxia
Peripheral neuropathy
Loss of vibratory sense
Myopathy
Vision loss
Haemolytic anaemia
Impaired neutrophil 
chemotaxis
Potentiation 
vitamin K deficiency 
Coagulopathy
Diarrhoea
Hyperosmolality 
(TPGS)
Alpha-Tocopherol (acetate)
25 - 200 IU/kg/d
TPGS (Luiqi E) 15 - 25 IU/kg/d
Vitamin K Deficiency:
Prolonged PTT/INR
Elevated PIVKA-II
Haemorrhagic disease
Excessive bruising
Vitamin K 2.5 - 5 mg, 2 - 7 times/wk
Intravenous vitamin K 2 - 10 mg may 
be required
Water-soluble 
vitamins
Multivitamin preparation providing 
1 - 2 times RDI
Minerals and trace elements
Iron Deficiency:
Decreased iron level, 
increased total iron-
binding capacity
Pallor
Koilonychia
Stomatitis
Teeth staining 
Haemorrhagic 
gastroenteritis 
Metabolic acidosis 
Coma, liver failure
Elemental iron 5 - 6 mg/kg/d
Zinc Deficiency:
Plasma zinc level 
<60 µg/dL
Alopecia, thin sparse hair
Acrodematitis 
enterohepatica
Decreased intestinal 
absorption copper 
and iron
Zinc sulphate solution 10 mg/mL 
elemental zinc
Elemental zinc 1 mg/kg/d
Selenium Deficiency:
Plasma selenium 
<40 µg/L
Dermatological 
changes
Diarrhoea
Dyspepsia
Anorexia
1 - 2 µg/kg/d oral sodium selenite or 
1 - 2 µg/kg/d selenium in TPN
Magnesium Deficiency:
Serum magnesium 
<0.7 mmol/L
Respiratory 
depression
Lethargy 
Coma
Magnesium oxide 
0.5 - 1 mmol/kg daily po, or 50% 
solution of magnesium sulphate 
0.01 - 0.25 mmol/kg IV over 3 - 6 h
Calcium Deficiency in steatorrhoea 
despite corrected 
vitamin D status
Poor dentition Hypercalcaemia
Hypercalciuria 
25 - 100 mg/kg/d up to 
800 - 1 200 mg/d
Phosphorus Low serum phosphorus 
level despite corrected 
vitamin D and calcium 
status
Gastrointestinal 
intolerance
25 - 50 mg/kg/d up to 500 mg/d
MCT = medium-chain triglyceride; po = orally; PTT = partial thromboplastin time; TPN = total parenteral nutrition; RDI = recommended daily intake.
Adapted from Nightingale & Ng,[6] Suchy et al.,[9] Sultan et al.,[15]  Cameron & Kogan-Liberman,[16]  Murray & Horslen.[17]
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treatment. Nutritional status is assessed at the first and all subsequent 
visits.
A dietary history identifies the type and quantity of feeds taken. 
In the case of formula-fed infants calculation of daily intake is easier 
than in the toddler and older child on a mixed diet. Determining the 
variety of foods ingested is important as children with restricted diets 
are at risk of micronutrient deficiency. Asking parents to keep a dietary 
diary is useful to obtain this information. Symptoms such as vomiting, 
anorexia, diarrhoea or steatorrhoea, and pale stools further identify 
those children at risk of poor intake and malabsorption. Assessment of 
the nutritional status also includes assessment of subcutaneous fat and 
muscle mass and signs of micronutrient deficiency. 
Anthropometry, the mainstay of nutritional assessment in 
most children, is influenced by changes in body composition in 
children with CLD. Weight-for-age and weight-for-height-for-age 
measurements usually underestimate the degree of malnutrition 
because of coexisting organomegaly, ascites and fluid retention. 
Stunting reflects chronic undernutrition; length or height should be 
accurately measured. However, in the presence of genetic conditions 
such as Alagille syndrome, stunting may be due to the underlying 
defect rather than malnutrition.
Skinfold thickness and mid-upper-arm circumference are less 
influenced by oedema and provide a more reliable estimate of 
nutritional status in these children. Skinfold thickness, measured over 
the triceps and subscapular areas, allows assessment of fat mass. These 
measurements require use of specialised calipers and appropriate 
training. Mid-upper-arm circumference is a useful tool that assesses 
muscle mass and can be compared with normal values for age.
Essential fatty acids or the triene:tetraene ratio can be determined 
in children with suspected essential fatty acid deficiency. These tests 
are often not available in routine laboratories in South Africa (SA).
Fat-soluble vitamin status should be assessed every 6 months or 
more frequently in the presence of deficiency. Biochemical vitamin A 
deficiency occurs before the deficiency becomes clinically overt. Serum 
retinol does not always accurately estimate vitamin A status in children 
with liver disease. The relative dose response may be more reliable but 
is not routinely performed.[13] The molar ratio of plasma retinol:retinol-
binding protein (RBP) has been suggested as an alternative (serum 
retinol (µg/dL)/serum RBP (mg/dL) × 0.0734: normal 0.8 - 2.0);[14] 
results of studies assessing this measure are however equivocal and 
most laboratories in SA do not routinely determine RBP.
Children with CLD require regular assessment for evidence of 
vitamin D deficiency and bone disease. This includes a history of bone 
pain and fractures, palpation of the spine and assessment of pubertal stage. 
Laboratory evaluation would include 25-OH vitamin D, parathyroid 
hormone, calcium, phosphate, magnesium, and alkaline phosphatase. 
Hand X-rays are valuable to evaluate the severity of osteodystrophy and 
the growth potential. Dual-energy X-ray absorptiometry to detect low 
bone mass and lateral spine X-ray to determine the presence of vertebral 
fractures may be required in older children.
Vitamin E deficiency is common in cholestatic liver disease. 
Initially asymptomatic, children develop peripheral neuropathy, 
spinocerebellar degeneration, and ataxia. Early in the disease these 
changes are reversible but, if treatment is delayed, may become 
permanent. In the presence of hyperlipidaemia, a frequent finding 
in cholestatic liver disease, vitamin E levels may be falsely normal; 
the ratio of tocopherol:total lipids or tocopherol:cholesterol should 
therefore be assessed to screen for vitamin E deficiency.
Laboratories in SA do not determine protein induced in vitamin K 
absence (PIVKA) for vitamin K deficiency. Prothrombin time or inter-
national normalised ratio (INR) are frequently used to assess for 
vitamin K deficiency; it should be kept in mind that these measures are 
also influenced by liver synthetic function. The response to parenteral 
vitamin K supplementation indicates whether abnormalities are due 
to liver failure or vitamin K deficiency. Although coagulopathy is the 
major complication of vitamin K deficiency, bone disease may also be 
due to carboxylation defects in vitamin K deficiency.
Trace-element deficiency occurs in children with CLD. Zinc and 
selenium deficiencies are common and serum zinc levels should 
be determined in children who are not growing satisfactorily. Iron 
deficiency also commonly occurs, particularly in children with portal 
hypertension.
Plasma proteins (albumin, prealbumin, RBP) are less useful in 
children with CLD as their levels are influenced by hepatocellular 
function and systemic inflammation. Bioelectrical impedance has little 
value in the nutritional assessment of these children.
Table 1 summarises the clinical nutritional assessment of children 
with CLD.
Nutritional support
The goals of nutritional support in children with CLD are normal 
growth and body composition and the prevention of vitamin and 
trace-element deficiency. Nutritional support should not be delayed, 
particularly in young infants. Intake should be reviewed regularly. 
Severity of disease, presence of complications, levels of activity and 
age-related changes in nutritional requirements should be taken into 
account. This requires expertise that is often beyond the scope of the 
family physician and paediatrician. A dietitian, experienced in the 
management of children, should be involved early in the course of 
the child’s disease.
In the absence of malnutrition, energy requirements can initially 
be considered to be normal. However, if growth is not satisfactory, 
high energy intake is encouraged. Intakes of 130 - 150% of normal 
energy intake are recommended. This is achieved by increasing fat 
and carbohydrate intake.
Increasing the fat intake increases total fat absorption. Medium-
chain fatty acid absorption is not dependent on bile salts and diets are 
supplemented with these fatty acids. They should not exceed 80% of 
the total fat intake as essential fatty acid deficiency may ensue. Long-
chain polyunsaturated fatty acids are essential for normal growth and 
brain development. Diets are enriched with foods that are rich in 
these fatty acids, e.g. egg yolk and vegetable oils. 
Carbohydrates are an important energy source in children. Diets 
should contain adequate carbohydrate to meet the child’s energy 
requirements without causing osmotic diarrhoea. This is usually not 
a problem in children receiving normal foods; however, for those 
receiving enteral feeds, selection of a formula with glucose polymers 
and not sugars may be necessary. In children with galactossaemia, 
galactose-free diets are required.
Protein restriction limits normal growth and should be avoided. 
Intakes of 3 - 4 g/kg/day (minimum 2 g/kg/day)[14] are encouraged. 
Although moderate elevations of ammonia  are often present, this 
should not prompt prolonged protein restriction in the absence of 
encephalopathy. 
Branched-chain amino acid supplementation has been shown to 
improve lean body mass gain. However, formulas enriched with these 
amino acids are expensive and are not readily available in SA.
Fat-soluble vitamin deficiencies frequently occur in children 
with cholestatic liver disease. This is predominantly due to fat mal-
absorption. These children often require high-dose supplemen tation 
and in some cases parenteral administration of vitamins. A water-
soluble preparation of vitamin E (TPGS) improves the absorp tion 
of other fat-soluble vitamins. Unfortunately this preparation is not 
available in SA.
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Children are supplemented with 5 000 - 10 000 IU of vitamin A 
daily. Occasionally higher doses (up to 25 000 IU/day) are required,[1] 
particularly in infants who have severe cholestatic liver disease. 
Care should be taken to avoid vitamin A toxicity which may cause 
pseudotumor cerebri, hypercalcaemia, painful bone lesions and liver 
toxicity.
Vitamin E deficiency is particularly difficult to treat in children 
with severe cholestasis. In the absence of TPGS, high-dose vitamin E 
supplementation is often required to prevent vitamin E deficiency. The 
starting dose is usually 10 - 25 IU/kg/day; this is increased as required 
to 100 - 200 IU/kg/day. Regular assessment of serum levels is required 
for dose titration.
Oral vitamin K supplementation is usually adequate to prevent 
severe vitamin K deficiency-associated coagulopathy. Children are 
given 2.5 - 5 mg/day although supplementation three times per week 
is often adequate to prevent coagulopathy. 
All children with CLD require vitamin D supplementation. 
The dose is determined by age, severity of liver disease, and the 
presence of complications such as rickets. Cholecalciferol is most 
frequently used to replenish vitamin D stores and prevent the 
complications of vitamin D deficiency. Alphacalcidol or calcitriol, active 
vitamin D metabolites, do not replace vitamin D stores, but are used to 
increase calcium absorption or to treat coexisting renal failure. These 
metabolites are usually added in children who have failed standard 
cholecalciferol supplementation and should not be used in isolation 
to treat vitamin D deficiency. Serum calcium and phosphate levels 
and urinary calcium should be monitored to avoid vitamin D toxicity. 
Children with vertebral fractures and evidence of low BMD may 
benefit from treatment with bisphosphonates and should be referred 
to bone specialists where possible.[8]
Supplementation aims to maintain a serum 25-OH vitamin D level 
of >50 nmol/L and a parathyroid hormone of <55 pg/mL. Children 
with a 25-OH vitamin D level >25 nmol/L are given 3 - 10 times the 
normal requirement (1 200 - 4 000 U/day); if the 25-OH vitamin D 
level is <25 nmol/L, the dose is increased to 6 000 - 25 000 U/day until 
normal levels are achieved. In the event of unsuccessful oral therapy, 
intramuscular vitamin D can be given monthly until normalisation of 
the serum vitamin D.[8] 
Dietary support of children with CLD also addresses trace element 
deficiency and sodium load. Supplementation with zinc, as well as 
other trace elements such as selenium, improves appetite and growth.
Sodium intake is restricted, particularly in those children with 
ascites. Fluid intake is not routinely restricted with the exception of 
children in hepatic failure.
Routes of feeding
Most children can be fed orally. Although liver-specific enteral feeds 
are not available in SA, modular feeds and other specialised infant 
formulas are useful in their management. Formulas developed 
for preterm infants have a high energy and mineral content and 
are enriched with medium-chain fatty acids. These formulas are 
often used to feed infants with cholestatic liver disease who are 
unable to breastfeed. Breastfed infants may require fortification or 
supplementation with medium-chain fatty acids.
Children with advanced liver disease require more frequent feeds 
as a result of rapid glycogen depletion in the fasting state and the 
risk of hypoglycaemia. These children often also have significant 
anorexia and require supplemental nasogastric feeds. Overnight 
nasogastric feeds are recommended in children who are unable to 
take in enough food to supply energy requirements. Nasogastric 
tubes are well tolerated by most of these children and do not increase 
the risk of bleeding in portal hypertension. If enteral feeds fail, 
parenteral nutrition is considered in consultation with a paediatric 
gastroenterologist and paediatric dietitian.
Although not an absolute contraindication, placement of a 
percutaneous endoscopic gastrostomy (PEG) is usually avoided in 
these children. Constant infusion feeds are given to children who 
are unable to tolerate bolus feeds. Regardless of the route or manner 
of feeding, oral feeding skills should be maintained to allow easier 
transition to full oral feeds at a later stage. The assistance of a speech 
and language therapist may be warranted.
Conclusions
Malnutrition is an important complication of CLD in children. 
Survival and quality of life are improved with early initiation of 
an active nutritional support programme. Most components of 
nutritional monitoring and supplementation can competently be 
implemented by the family physician and general paediatrician. 
However, given the complexity of the diseases, a paediatric gastro-
enterologist or hepatologist, together with a paediatric dietitian, 
should be involved in the treatment of these children from an early 
stage of their disease.
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